IYJ
(6M)-6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Find entries where: IYJ
is present as a standalone ligand in 1 entries
Chemical Component Summary | |
---|---|
Name | (6M)-6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine |
Identifiers | 6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine |
Formula | C9 H7 Cl2 N5 |
Molecular Weight | 256.091 |
Type | NON-POLYMER |
Isomeric SMILES | c1cc(c(c(c1)Cl)Cl)c2c(nc(nn2)N)N |
InChI | InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16) |
InChIKey | PYZRQGJRPPTADH-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 23 |
Chiral Atom Count | 0 |
Bond Count | 24 |
Aromatic Bond Count | 12 |
Drug Info: DrugBank
DrugBank ID | DB00555 |
---|---|
Name | Lamotrigine |
Groups |
|
Description | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries.[A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850] |
Synonyms |
|
Brand Names |
|
Indication | Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.[L9404] It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).[L9404] In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy.[L9404] Limitations of use It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.[L9404] |
Categories |
|
ATC-Code | N03AX09 |
CAS number | 84057-84-1 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E) | MARFGEAVVARPGSGDGDSDQSRNRQGTPVPASGQAAAYKQTKAQRARTM... | unknown | inhibitor |
Voltage-gated sodium channel alpha subunit | MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK... | unknown | inhibitor |
Adenosine receptor A1 | MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVS... | unknown | inhibitor |
Adenosine receptor A2a | MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA... | unknown | inhibitor |
Alpha-1A adrenergic receptor | MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL741 |
PubChem | 3878 |
ChEMBL | CHEMBL741 |
ChEBI | CHEBI:6367 |